Ascentage Pharma: Trustee Purchases 190,000 Shares to Fund 2022 RSU Scheme

Bulletin Express

Jun 10

Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme acquired 190,000 existing shares on-market on 10 June 2026 to satisfy future vesting obligations.

The purchase was executed at an average price of HK$33.78 per share, representing a total cash outlay of HK$6.42 million, excluding related fees and levies. The newly acquired shares equal approximately 0.0509% of the company’s issued share capital.

Following this transaction, the trustee holds 2.51 million shares under the 2022 RSU Scheme. In line with the trust deed, the trustee will not exercise voting rights attached to any shares it holds.

The company reiterated that, aside from the initial and subsequent grants disclosed on 23 June 2022, 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, and 20 April 2026, no additional awards have been granted under the 2022 RSU Scheme.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159715808"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159715808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159715808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159715808","market":"us","top_or_hot":-1,"title":"Ascentage Pharma: Trustee Purchases 190,000 Shares to Fund 2022 RSU Scheme","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme acquired 190,000 existing shares on-market on 10 June 2026 to satisfy future vesting obligations.</p>\n<p>The purchase was executed at an average price of HK$33.78 per share, representing a total cash outlay of HK$6.42 million, excluding related fees and levies. The newly acquired shares equal approximately 0.0509% of the company’s issued share capital.</p>\n<p>Following this transaction, the trustee holds 2.51 million shares under the 2022 RSU Scheme. In line with the trust deed, the trustee will not exercise voting rights attached to any shares it holds.</p>\n<p>The company reiterated that, aside from the initial and subsequent grants disclosed on 23 June 2022, 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, and 20 April 2026, no additional awards have been granted under the 2022 RSU Scheme.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma: Trustee Purchases 190,000 Shares to Fund 2022 RSU Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma: Trustee Purchases 190,000 Shares to Fund 2022 RSU Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-10 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme acquired 190,000 existing shares on-market on 10 June 2026 to satisfy future vesting obligations.</p>\n<p>The purchase was executed at an average price of HK$33.78 per share, representing a total cash outlay of HK$6.42 million, excluding related fees and levies. The newly acquired shares equal approximately 0.0509% of the company’s issued share capital.</p>\n<p>Following this transaction, the trustee holds 2.51 million shares under the 2022 RSU Scheme. In line with the trust deed, the trustee will not exercise voting rights attached to any shares it holds.</p>\n<p>The company reiterated that, aside from the initial and subsequent grants disclosed on 23 June 2022, 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, and 20 April 2026, no additional awards have been granted under the 2022 RSU Scheme.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1159715808","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159715808","pubTimestamp":1781096608,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme acquired 190,000 existing shares on-market on 10 June 2026 to satisfy future vesting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"亚盛医药：受讬人购买190,000股股份为2022年受限制股份单位计划提供资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme acquired 190,000 existing shares on-market on 10 June 2026 to satisfy future vesting obligations.\nThe purchase was executed at an average price of HK$33.78 per share, representing a total cash outlay of HK$6.42 million, excluding related fees and levies. The newly acquired shares equal approximately 0.0509% of the company’s issued share capital.\nFollowing this transaction, the trustee holds 2.51 million shares under the 2022 RSU Scheme. In line with the trust deed, the trustee will not exercise voting rights attached to any shares it holds.\nThe company reiterated that, aside from the initial and subsequent grants disclosed on 23 June 2022, 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, and 20 April 2026, no additional awards have been granted under the 2022 RSU Scheme.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}